European Federation of Neurological Associations (EFNA) Amanda Worpole Executive Director, EFNA Our Vision: A better quality of life for people in Europe living with a neurological disorder. Our Mission To influence policy makers and legislators in Europe To communicate with our members to achieve positive change To establish strong partnerships and alliances

The world is living longer A baby girl born in Japan has a 50/50 chance of living 100 years

Global ageing in the 21 st century The world stands on the threshold of a social transformation - even a revolution - with few parallels in humanity's past.... perhaps two-thirds of all people who have ever reached the age of 65 are alive today. Peter G. Peterson

European Brain Council study The number of persons with defined disorders of the brain in Europe in 2010 The total cost per person per year related to each disease by specifying direct and indirect costs The total cost per disorder and country The total cost of brain disorders in all of Europe Cost of Disorders of the Brain in Europe 2010 Gustavsson et al. Cost of disorders of the brain in Europe Eur. Neuropsych. (2011) 21,

Cost of brain disease Dementia - 16,584 per patient per year; 105,163 million in total Parkinsons disease - 11,153 per patient per year; 13,933 million in total Stroke per patient per year; 64,053 million in total

Policy Implications for European Research Insufficient funding for disorders of the brain From a societal perspective, the return on investment in brain research far exceeds the return from any other branches of research FP7: Specific mention of brain research Horizon 2020: must address clinical and basic brain research

Policy implications for European health care Further increase of the burden due to the increasing trend in life expectancy in Europe A coordinated policy covering all disorders of the brain is needed Increased focus on prevention should be of high priority

P olicy implications for European health educators Only 8% of clinical education at medical schools for psychiatry and neurology. Even less in other health professions Treatment for brain disorders have drastically improved. Increased curricula and teaching efforts are needed

Policy implications - European pharmaceutical industry Pharmaceutical industry moving out of Europe Investments in drugs for brain disappointing Drug development for brain disorders is declining Unnecessary regulatory barriers to drugs

Social and Personal Activities relationships with friends pastimes and hobbies family members holidays/breaks Anxiety and Depression mental health and well-being Anxiety lack of energy and motivation depression. The PDQ-Carer

Self-care: health health behaviour Stress feelings of impatience and anger feelings of being undervalued weighed down by responsibilities.

Clinical trails & medicines Inclusion of older people in clinical trials real life includes co-morbidities & polypharmacy Side effects Drug interactions Protocols Outcomes: beyond the clinical Information for patients Pharmacovigilance

Risk factors from conception onwards Need to take care of our brains Healthy diet Stay away from tobacco Modest alcohol intake Avoid recreational drugs Drink water

Thank you